The US Food and Drug Administration (FDA) is close to approving the first nation's RSV vaccine, developed by Pfizer, which has been shown to reduce the risk of illness from RSV by as much as 86%. The Vaccines and Related Biological Products Advisory Committee voted 7-4 in favor of the vaccine, despite some safety concerns. If approved, the vaccine would be the first of its kind in the US and provide a much-needed protection against RSV for older adults.
